JPMorgan發展中市場股票主動型ETF JADE 深 滬
等待開盤 10-28 09:30:00 美东时间
73.4997
+0.793
+1.09%
華盛通- 最 高73.73
- 今 開73.15
- 成交量 2237股
- 最 低 73.15
- 昨 收 72.7065
- 總市值 2939.99万
- 52周最高 82.75
- 市盈率 靜 --
- 換手率 0.56%
- 52周最低 58.9833
- 委 比 0.00%
- 總股本 40.00万
- 歷史最高 82.75
- 量 比 0.49
- 振 幅 0.80%
- 歷史最低 40.7433
- 每 手 1
- 風險率 6.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jade Biosciences to Highlight Advancement of JADE101 Development Program at American Society of Nephrology (ASN) Kidney Week 2026
Jade Biosciences announced at ASN Kidney Week 2026 that three posters on JADE101, an anti-APRIL monoclonal antibody for IgA nephropathy, will be presented. The posters highlight the planned acceleration of the EVERGREEN Phase 3 trial, now expected to begin in Q4 2026, and interim data from the ongoing JUNIPER Phase 2 trial, anticipated in Q2 2027. The company expressed confidence in JADE101's potential to achieve sustained IgA reductions with qua...
10-21 11:00
Jade Biosciences advances JADE301 toward Phase 1 trial
The latest announcement is out from Jade Biosciences ( ($JBIO) ). On September ...
09-30 19:28
Jade Biosciences, Inc. GAAP EPS of -$0.76
Jade Biosciences, Inc. press release (JBIO): Q2 GAAP EPS of -$0.76. Cash Position: As of June 30, 2026, Jade had cash, cash equivalents, and investments of $461.2 million. Based on its current operati...
08-11 01:37
Jade Biosciences plans public offering, pre-funded warrants
Jade Biosciences (JBIO) on Wednesday said it intends to offer shares of common stock and, in lieu of common stock for certain investors, pre-funded warrants in an underwritten public offering. The com...
06-04 04:26
Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences reports Phase 1 JADE101 data showing sustained IgA reductions in IgAN, while analyst addresses ADA concerns and timeline expectations.
06-02 01:59
Jade Biosciences Doses First Patient In Phase 1 Clinical Study Of JADE201; Anticipates Interim First-In-Human Data Next Year
Jade Biosciences, Inc. ("the Company" or "Jade"), (NASDAQ:JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has
05-27 04:06
业聚医疗（6929.HK）：全年业绩再创新高，核心经营利润增20.2%，全球化与创新双轮驱动彰显韧性
2025年，全球医疗器械行业仍在关税扰动与地缘政治变局中艰难前行。业聚医疗却逆势交出一份硬核成绩单：收入与销量连续五年创下历史新高，核心经营利润同比猛增20....
03-16 08:51
